Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior ChemotherapyGeorge D. Demetri, Jean‐Yves Blay, Arthur P. Staddon et al.|Journal of Clinical Oncology|2013Cited by 243
Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.Jean‐Yves Blay, George D. Demetri, Sant P. Chawla et al.|Journal of Clinical Oncology|2012Cited by 11